IP Library Granted Patent US 11,324,912
Granted Patent B2
US 11,324,912 · App. 16/696,142 · Granted May 10, 2022

Systems and methods for indicating lifetime of an NO

Inventors: Jaron Acker (Madison, WI); Muhammad Asif (New Fairfield, CT); Craig Flanagan (Belmar, NJ); Douglas Alan Greene (Basking Ridge, NJ); Sarah Jayne Ridley (Philipsburg, NJ); Frank Kenneth Schweighardt (Allentown, PA); Lien-Lung Sheu (Berkeley Heights, NJ)
Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
A61M16/12A61M16/0051A61M16/024A61M16/06A61M16/10B01D53/0415C01B21/24A61M16/0063A61M16/16A61M16/161A61M16/202A61M2016/003A61M2016/1035A61M2202/0275A61M2205/12A61M2205/18A61M2205/3306A61M2205/3317A61M2205/3324A61M2205/3368A61M2205/3569A61M2205/3592A61M2205/50A61M2205/581A61M2205/583A61M2205/584A61M2205/707B01D53/0446B01D2253/106B01D2257/404B01D2259/4533
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,324,912
App. No.
16/696,142
Granted
May 10, 2022
Kind
B2
Abstract

The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO 2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a break-through of NO 2 , and providing an indication of the remaining useful life and/or break-through.

Claims (34)

1. A system for safely delivering a supply of nitric oxide (NO) to a recipient, comprising:

a gas source that supplies a gas, wherein the gas supplied by the gas source is nitrogen dioxide (NO 2 );

a gas conduit connected to and in fluid communication with the gas source;

a NO 2 -to-NO reactor cartridge connected to and in fluid communication with the gas conduit, so as to allow gas to flow from the gas source to an inlet end of the NO 2 -to-NO reactor cartridge, wherein the NO 2 -to-NO reactor cartridge further comprising an outlet end and an internal volume comprising a consumable conversion media;

one or more sensor probe(s) is configured to be inserted through an opening of a wall of the NO 2 -to-NO reactor cartridge and into the internal volume of the NO 2 -to-NO reactor cartridge and is configured to monitor the functioning of the NO 2 -to-NO reactor cartridge operatively associated with the NO 2 -to-NO reactor cartridge, wherein the one or more sensor probe(s) are selected from a group consisting of one or more cannula sensor probe(s) and one or more fiber optic sensor probe(s);

a delivery conduit connected to and in fluid communication with an outlet end of the NO 2 -to-NO reactor cartridge, wherein the delivery conduit is operable to allow NO gas from the NO 2 -to-NO reactor cartridge to flow to the recipient;

a computer in electronic communication with the one or more sensor probe(s) over a communication path, wherein the computer is configured to receive electronic signals from the one or more sensor probe(s) and calculate a performance value; and

a regulating means in electronic communication with the computer over a communication path; wherein the regulatory means is controlled based on the performance value.

2. The system of claim 1 , wherein the gas sample is communicated through a sample tube to an injector of a gas chromatograph for analysis.

3. The system of claim 2 , wherein the one or more cannula sensor probe(s) and gas chromatograph monitor the functioning of the conversion reactor and determine a lifetime of the conversion media.

4. The system of claim 1 , wherein the internal volume further comprises a coated porous material at the outlet end of the reactor and the one or more fiber optic sensor probe(s) are operable to receive a signal from at least one surface of the coated porous material.

5. The system of claim 4 , wherein the coated porous material comprises a color-active agent.

6. The system of claim 5 , wherein the one or more fiber optic sensor probe(s) supplies a radiant source, and the one or more fiber optic sensor probe(s) receives light reflected off of the color-active agent and communicates the light to a spectrometer for wavelength detection and intensity measurement.

7. The system of claim 1 , further comprising a flow meter for measuring an amount of gas entering the NO 2 -to-NO reactor cartridge.

8. The system of claim 1 , further comprising a flow meter for measuring an amount of gas being delivered to the recipient.

9. The system of claim 1 , further comprising an NO 2 sensor operationally associated with the delivery conduit configured to determine a presence of an unacceptable level of NO 2 in the gas being directed to the recipient.

10. The system of claim 1 , wherein the performance value is calculated and utilized for comparison with a predetermined threshold value, the computer is configured to generate an actuating signal when the performance value falls below the threshold value, and the regulating means is configured to receive the actuating signal from the computer, wherein the regulating means is configured to halt the delivery of the gas to a recipient when the actuating signal is received from the computer.

11. The system of claim 10 , wherein the threshold value indicates that a predetermined amount of the consumable conversion media has been reached, and wherein the computer is configured to alert a user through a display, an audible alarm, or both that the NO 2 -to-NO reactor cartridge is exhausted or compromised.

12. A method of monitoring the performance of a nitrogen dioxide (NO 2 )-to-nitric oxide (NO) reactor cartridge, the method comprising:

incorporating one or more sensor probe(s) into an NO 2 -to-NO reactor cartridge comprising a conversion media in an internal volume, wherein the one or more sensor probe(s) are operatively associated with the NO 2 -to-NO reactor cartridge, wherein the one or more probe(s) is configured to be inserted through an opening of a wall of the NO 2 -to-NO reactor cartridge and into the internal volume of the NO 2 -to-NO reactor cartridge and the one or more sensor probe(s) are selected from a group consisting of one or more cannula sensor probe(s) and one or more fiber optic sensor probe(s); and

operatively associating at least one meter with the one or more sensor probe(s) and wherein the one or more sensor probe(s) are embedded into the conversion media;

calculating a performance value based on electronic signals from the one or more sensor probe(s); and

controlling a regulating means based on the performance value.

13. The method of claim 12 , further comprising obtaining samples of gases present at one or more sample points in the NO 2 -to-NO reactor cartridge from the one or more cannula sensor probe(s).

14. The method of claim 13 , further comprising:

communicating a gas sample of the gas samples through a sample tube to an injector of a gas chromatograph for analysis;

monitoring the functioning of the conversion reactor with a computer; and

determining a lifetime of the conversion media.

15. The method of claim 12 , wherein the internal volume of the NO 2 -to-NO reactor cartridge further comprises a coated porous material at an outlet end of the reactor and the one or more fiber optic sensor probe(s) are operable to receive a signal from at least one surface of the coated porous material.

16. The method of claim 15 , wherein the coated porous material comprises a color-active agent.

17. The method of claim 16 , further comprising:

supplying a radiant source from the one or more fiber optic sensor probe(s) supplies;

receiving light reflected off of the color-active agent in the one or more fiber optic sensor probe(s); and

communicating the light to a spectrometer for wavelength detection and intensity measurement.

Assignments (14)
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); STRATATECH CORPORATION
Reel/Frame 065712/0988 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 052456, FRAME 0158 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0133 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 056433/0640 →
CHANGE OF NAME Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 056476/0162 →
SECURITY INTEREST Recorded Apr 22, 2020
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; OCERA THERAPEUTICS, INC.; ST SHARED SERVICES LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 052463/0396 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Apr 21, 2020
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 052456/0158 →